Ultra-long acting insulin-Fc fusion proteins and methods of use
AssigneeAkston Biosciences Corporation
InventorsThomas M. Lancaster, Todd C. Zion
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for lowering the blood glucose of a target subject, including for treating diabetes, by administering recombinantly manufactured ultra-long acting insulin-Fc fusion proteins.
Claims12
A method for lowering the blood glucose of a target subject, the method comprising administering a physiologically effective amount of a fusion protein or a pharmaceutical composition thereof to the target subject, wherein the fusion protein comprises an insulin polypeptide and an Fc fragment, wherein the insulin polypeptide and the Fc fragment are connected by a linker, wherein the fusion protein comprises the following sequence:
- (SEQ ID NO:
- 87)
- FVNQHLCGSHLVEALALVCGERGFHYGGGGGGSGGGGGIVEQCCTSTCS
- LDQLENYCGGGGGQGGGGQGGGGQGGGGGDKTHTCPPCPAPELLGGPSV
- FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
- KPREEQYSSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK
- AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
- ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFScSVMHEALHNHY
- TQKSLSLSPG.
Dependencies are inferred from the claim text.